Paradigm Biopharmaceuticals (ASX:PAR) has announced the peer reviewed publication validating the efficacy of PPS in experimental allergic rhinitis using an industry standard preclinical model.
The company welcomed publication in the peer-reviewed scientific journal, 'Immunity, Inflammation and Disease', of the preclinical study validating the efficacy of PPS as a non-steroidal agent in allergic rhinitis.
According to lead author Professor Erjefält from Lund University in Sweden, “The commercial formulation of the corticosteroid budesonide was used as a reference drug. Across the efficacy parameters, PPS and budesonide displayed similar anti-inflammatory profiles. Despite the multiple targets that PPS binds, the therapeutic effects are broad immunomodulation rather than the immunosuppression observed for corticosteroids. This means that the side-effects encountered with steroidal medication would not be experienced with PPS based treatments”.
Paradigm’s chief scientific officer, Dr Ravi Krishnan, said, “The publication highlights the clinically significant finding that PPS binds to the key cytokines involved in allergic rhinitis. Other clinically relevant effects of PPS included the statistically significant reduction in the influx of white cells into the nasal lumen. Importantly, the significant inhibitory effect by PPS on plasma protein leakage in the nasal lumen demonstrates the potential of PPS as an anti-allergic drug. This means that PPS has the potential to safely address the key symptoms of hay fever, namely the runny nose, sneezing, itchy eyes and associated inflammation of the nasal passage”.
“Mr. Rennie further remarked that “this peer-reviewed publication provided the basis for Paradigm’s clinical development program to assess its PPS based nasal product, Rhinosul, in a Phase 2a clinical trial," said Paradigm CEO, Mr Paul Rennie.
The Phase 2a study is a double blind, placebo controlled, cross-over allergen challenge study treating subjects with hay fever and is being conducted in Sweden.